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Abstract:  Following our recent study of N-(β-D-glucopyranosyl)-oxadiazole-carboxamides 
(Polyák et al., Biorg. Med. Chem. 2013, 21, 5738) revealed as moderate inhibitors of 
glycogen phosphorylase (GP), in silico docking calculations using Glide have been performed 
on N-(β-D-glucopyranosyl)-1,2,4-triazolecarboxamides with different aryl substituents 
predicting more favorable binding at GP. The ligands were subsequently synthesized in 
moderate yields using N-(2,3,4,6-terta-O-acetyl-β-D-glucopyranosyl)-tetrazole-5-carboxamide 
as starting material. Kinetics experiments against rabbit muscle glycogen phosphorylase b 
(RMGPb) revealed the ligands to be low µM GP inhibitors; the phenyl analogue (Ki = 1 µM) 
is one of the most potent N-(β-D-glucopyranosyl)-heteroaryl-carboxamide-type inhibitors of 
the GP catalytic site discovered to date. Based on QM and QM/MM calculations, the potency 
of the ligands is predicted to arise from favorable intra- and intermolecular hydrogen bonds 
formed by the most stable solution phase tautomeric (t2) state of the 1,2,4-triazole in a 
conformationally dynamic system. ADMET property predictions revealed the compounds to 
have promising pharmacokinetic properties without any toxicity. This study highlights the 
benefits of a computationally lead approach to GP inhibitor design. 
 
Keyword: 1,2,4-triazole, β-D-glucopyranosyl derivatives, glycogen phosphorylase, inhibitor, 
ADMET, docking, QM/MM 
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Introduction 
Type 2 diabetes mellitus (T2DM) is characterized by hyperglycemia and peripheral insulin 
resistance, and represents more than 90% of all diabetic cases. The significant increase in the 
global incidence of diabetes is a major cause for concern, having doubled over the previous 3 
decades to 347 million people in 2008.1 Without adequate control of blood glucose levels, 
T2DM has several long term complications such as neuropathy and nephropathy, as well as an 
increased risk of blindness and cardiovascular disease.2 Glycogen phosphorylase (GP; EC 
2.4.1.1) is a validated target for T2DM having a direct influence on blood glucose levels 
through the glycogenolysis pathway.3 It is an allosteric enzyme with a number of different 
binding sites,4, 5 the catalytic, allosteric, new allosteric, inhibitor, glycogen storage, 
benzimiadazole6 and the very recently identified quercetin binding site.7 Significant efforts 
have been afforded to the design of GP inhibitors in recent years, with catalytic site inhibitors 
the most explored.4, 8, 9 The physiological inhibitor of GP is α-D-glucose (Ki = 1.7 mM), but 
β-substitutions at the anomeric carbon of D-glucose have led to the most effective GP 
catalytic site inhibitors and have demonstrated blood sugar lowering effects in vivo.10, 11  
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Figure 1. The four most potent glucose analogue inhibitors of GP discovered to date (1a,12 
1b,5 1c13, 14  and 1d15) together with their Ki’s for RMGPb inhibition. All ligands possess a 2-
napthyl substituent exploiting favorable interactions in the GP catalytic site β–cavity.   
An evaluation of the current status of β-D-glucopyranosyl analogues as GP inhibitors can be 
found in recent reviews.4, 8 The four most potent discovered to date are shown in Figure 1, all 
of which possess a 2-napthyl moiety exploiting favorable interaction of aryl groups in the 
catalytic β-cavity, a pocket lined by both polar and non-polar groups. In general, the 2-napthyl 
moiety has proved the most effective in terms of potency, but our recent studies on N-(β-D-
glucopyranosyl)-oxadiazole-carboxamides with linkers 2-4 (Table 1) have revealed that this is 
not always the case.16 However, these ligands only demonstrated moderate potency at best, 2b 
and 3c the most potent with Ki’s ~ 30 µM. The 1,2,4-triazole moiety in the form of 3-(β-D-
glucopyranosyl)-5-substituted-1,2,4-triazoles has very recently revealed some of the most 
potent inhibitors of the GP catalytic site,13, 14 with the 2-napthyl derivative (1c in Figure 1) the 
most potent. In the current work, we have investigated N-(β-D-glucopyranosyl)-3-substituted-
1,2,4-triazole-5-carboxamides, replacing the oxadiazole moiety of linkers 2-4 with a 1,2,4-
triazole (5, Table 1) in an attempt to improve ligand potency. Prior to undertaking synthesis, 
in silico calculations in  the form of Glide docking, quantum mechanics (QM) and quantum 
mechanics/molecular mechanics (QM/MM) calculations were performed to probe the binding 
potential of these ligands at GP. 
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Table 1. Inhibition constants (Ki [μM], RMGPb) and Emodel docking scores from Glide (in 
italics) for N-(β-D-glucopyranosyl)-oxadiazole-carboxamides 2-4, and N-(β-D-glucopyranosyl)-
1,2,4-triazolecarboxamides 5. The normalized values of Emodel are also shown in parentheses, 
as calculated using Eq. (1). 
O
HO
HO
HO
OH
H
N linker
O
Ar
 
Linker 
Scaffold 
Ar 
   
a b C 
Oxadiazoles     
NN
O  
2 
545* 
-92.31(-3.69) 
30 
-116.15(-4.01) 
172* 
-112.17(-3.87) 
ON
N  
3 
136* 
-100.68(-4.03) 
N.I.a 
-115.78(-3.99) 
33 
-117.65(-4.06) 
NO
N  
4 
104 
-100.15(-4.01) 
N.I.a 
-111.92(-3.86) 
145* 
-113.96(-3.93) 
1,2,4-triazoles     
NN
N
H  
5 
1 
-102.34(-4.09) 
9.2 
-116.52(-4.02) 
- 
-120.43(-4.15) 
a No inhibition. * Calculated from the IC50 values by the Cheng–Prusoff equation: Ki = IC50/(1 + 
[S]/Km).17  
 
Results & Discussion 
In Silico Binding Studies 
All ligands in Table 1 were prepared for calculations using Maestro and the LigPrep 2.5 
program18  generating minimized favorable tautomeric and ionization states of all ligands at 
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pH = 7+/-2. All ligands were assigned as neutral, but three tautomeric forms (t1, t2 and t3) of 
the 1,2,4-triazole (linker 5) were produced, with t1 and t2 the most probable based on LigPrep 
with Epik (Table 2).18 Monte Carlo conformational searches on models of ligands 5 and its 
three tautomers t1-t3 were performed followed by Jaguar 8.0 density functional theory (DFT) 
with M06-2X19 and the 6-31+G* basis set20, 21(M06-2X/6-31+G*), and yielded the 
conformations shown in Table 2.  Higher level M06-2X/cc-pVTZ++22 single point energy 
(SPE) calculations in gas and solution phase at these geometries revealed that while t1 is the 
most favored in the gas phase by ~ 6 kcal/mol, t2 is clearly preferred in solution (by ~ 9 
kcal/mol). This is in contrast to the tautomeric probabilities from LigPrep/Epik, highlighting 
the value of a QM approach to such analysis. Tautomer t2 also allows for approximately two 
equally stable conformations (ω = 0◦ or 180◦) in the free unbound solvated state, as defined by 
the dihedral angle ω defined in Table 2. The molecular electrostatic potentials (MESPs) are 
shown in Figure 2. For tautomer t2, the two different conformations have little effect on the 
ESPs of the amide. However, the ESP in the space around a gas phase molecule is a key 
factor in determining its ability to accept a proton; in this regard, for t2 (ω = 180◦) the 
maximum ESP of the triazole NH nitrogen (62.55 kcal/mol) and minimum ESP of the 
connected N (-50.84 kcal/mol) is consistent with H+ migration to form the most stable t1 
tautomer in the gas phase (Table 2). The intra-molecular NH (amide) and triazole N (lone 
pair) contacts for the tautomers can only loosely be classified as hydrogen bonds under the 
current IUPAC guidelines23 (donor angles are ~ 103-105◦, hence less than the preferred > 
110◦), however, there is evidence of charge transfer in the case of t1 and t2 tautomers where 
the magnitudes of the potential at the N are less ~ -15 kcal mol-1.  In any case, favourable 
electrostatic stabilization occurs between these atoms and the contacts are present in all free 
state conformations.   The conformational flexibility and MESP of t2 compared to the other 
tautomers become important factors when we consider the binding at GPb.  
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Table 2. Comparison of the relative energies (kcal/mol) of different tautomers and conformations of the 
1,2,4-triazole (linker 5) for models of the N-(β-D-glucopyranosyl)-1,2,4-triazolecarboxamides, as calculated 
using density functional theory.  For simplicity and speed, in the calculations the β-D-glucopyranose was 
replaced by a methyl group and a phenyl used for the Ar group. Geometries used in calculations were from 
M06-2X/6-31+G* optimizations.a 
Tautomer 
 
  Gas Phasec Solution Phasec,d 
Dihedral
Angle     
ω (◦)b 
LigPrep 
Tautomer    
Probability 
M06-2X/             
6-31+G* 
M06-2X/                 
cc-pVTZ++ 
 
 
M06-2X/                 
cc-pVTZ++ 
 
       
3
ω
4
1
2
N
N
O
N
O
O H
OH
OH
O H N
H
Ar
H
 
t1 
 
 
     180 
 
 
 
0.487 
 
 
 
       0.0(0.0)e 
 
      0.0 
 
          8.6 
 
O
OH
HO
HO
OH
H
N
O
NHN
N
Ar
 
t2 
 
 
       0 
     180 
 
 
0.487 
 
 
       6.5(7.2)e 
       5.9(6.9)e 
        
       5.9 
       5.3 
           
          0.5 
          0.0 
O
OH
HO
HO
OH
H
N
O
NN
N
H
Ar
 
t3 
 
 
       0 
 
 
 
0.027 
 
 
 
 
       5.9(6.4)e 
 
       5.5 
 
          9.0 
 
a Tautomeric states were determined using LigPrep.18 MacroModel 9.918 conformational searches were used 
to locate the above favorable conformations of the compounds, which were then used in the QM 
optimizations. The dihedral angle ω adopted by the atoms 1, 2, 3, 4 for rotation around the 2,3 bond is key 
to the conformational properties. b Values for the minima from the M06-2X/6-31+G* optimizations. cSingle 
point energy calculations at the optimized M06-2X/6-31+G* geometries. d Continuum treatment of 
solvation which involved accurate numerical solution of the Poisson-Boltzmann (PBF) equation.24, 25   
e Relative Gibbs free energies given in parentheses.  
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Figure 2. Molecular electrostatic potential (MESPs) can be used to provide insight into a 
number of hydrogen bonding phenomena. Shown are the results of MESP calculations (M06-
2X/6-31+G*) on a model of the isolated 5a ligand (Me groups instead of glucopyranose) in its 
different tautomeric forms and most stable conformations (Table 2). The electrostatic 
potentials are mapped onto the electron density surface for each molecule. Only the ESP 
range of -50–50 kcal mol-1 is used for a better visual demonstration of the tautomeric effects; 
actual minimum–maximum ESP values were -55.4 – 63.7  kcal mol-1 obtained for the t2 
tautomer. The minimum or maximum local electrostatic potential values (kcal/mol) for the 
relevant atoms are also shown.   
 
Docking calculations were performed using Glide 5.8 in extra-precision (XP) mode,18, 26 a 
docking algorithm which has proved effective in previous GPb catalytic site studies.15, 27, 28 
The predictive capability of Glide-XP in the current study was measured by the ability of the 
algorithm to reproduce the trends in the kinetics results for the N-(β-D-glucopyranosyl)-
oxadiazole-carboxamides with linkers 2-4. The results are shown in Table 1, with the most 
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consistent results obtained using the Emodel scoring function which combines GlideScore, 
the non-bonded interaction energy and the excess internal energy of the generated ligand 
conformation. Non-bonded interactions in a scoring function are typically calculated as a sum 
of pair-wise interactions. Hence, a larger compound often receives a more favorable score 
than a smaller compound. In order to overcome this bias, a number of different normalization 
and scaling approaches have been proposed.29, 30 Given that the aforementioned trend 
appeared to occur for our training set ligands, we used the following equation to account for 
the different sizes of our aryl substituents (phenyl versus napthyl): 
                                     Emodelnorm = Emodel/number of heavy atoms                         Eq.(1)  
On initial inspection of Table 1, the predictive capability of the docking does not appear 
obvious. For example, the score for 3b is clearly over-estimated. However, a reasonable 
correlation R2 = 0.67 between predicted (Emodelnorm) and experimental (ln Ki) binding 
strengths was obtained. Further, the most favorable aryl group for each of the linkers 2-4 was 
correctly predicted: 2-napthalene (2b) in the case of 2, 1-napthalene (3c) in the case of 3 (1-
napthalene) and phenyl (4a) in the case of 4. In terms of our key objective, to accurately 
predict the potential of linker 5, we noted that the most favorable linker (from 2-4) for each 
aryl group was also correctly identified: linker 2 in the case of 2-napthalene (Ki = 30 µM), 
linker 3 for 1-napthalene (Ki = 33 µM), and for phenyl the linkers 3 and 4 were predicted to 
have similar efficiency in line with kinetics (Ki’s = 104-136 µM). Encouraged by this, we then 
noted that for each of the phenyl, 1- and 2-naphthalence substituents, linker 5 was predicted 
to give rise to more potent ligands.   
Despite their obvious importance, tautomeric states are still often not accurately considered in 
computer-aided drug design efforts.31 The most favorable tautomeric state for binding of 
ligands 5a-5c based on Emodel docking scores was t2 for both 5a and 5c, and t1 for 5b 
(Table 3). The potential of using the lowest QM/MM complex energy for protein-ligand 
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docking pose selection has recently been highlighted, where QM/MM energies were used to 
re-rank docking poses and compared with their native crystallographic binding modes.32 
Accordingly, to more accurately probe the binding of 5a-5c and its different tautomers at GP, 
QM/MM optimizations with QSite 5.8 18 were performed on the Glide docking poses (Table 
3).  M06-2X/6-31+G* was used for the QM region (the ligands), while the GPb protein was 
described using MM with the OPLS-AA(2005) forcefield,33 with otherwise default options. 
Solution phase energies at the optimum geometries were then obtained, employing a self-
consistent reaction field (SCRF) continuum treatment for water solvation effects and which 
involved accurate numerical solution of the Poisson-Boltzmann (PBF) equation (M06-2X/6-
31+G* + PBF).24, 25 The results of the QM/MM calculations (Table 3) revealed the most 
stable free state solution phase t2 tautomer of 5a-5c to also form the most favorable 
complexes with GPb, in both gas and solution phases. From the MESPs (Figure 2) also, the t2 
maximum and minimum atomic ESPs of the triazole NH nitrogen and amide CO oxygen 
(both conformations) are indicative of greater H-bond acceptor and donor capabilities,34, 35 
respectively, for binding at GPb compared to the other tautomers, although the value of ESP 
maxima on molecular surfaces for predicting hydrogen bond acidity has recently been 
questioned.36   
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Table 3. QM/MM gas and solution phase relative energies (kcal/mol) for the optimized 
Glide docking poses of ligands 5a-5c considering the different tautomeric forms as 
described in the text. The corresponding Emodel docking scores are also shown.  
Ligand Tautomera Emodel 
(Emodelnorm)b 
ω  
dihedral 
angle(◦)c 
QM/MM relative energies 
Gas Phase Solution Phase 
5a t1 -99.8 (-3.99) 34.3 16.6 18.1 
 t1 -93.9 (-3.76) 178.0 7.7 19.6 
 t2 -102.3 (-4.09) 19.7 3.8 0.0 
 t2 -97.1 (-3.88) -176.7 0.0 10.7 
 t3 -91.0 (-3.64) 3.5 14.5 13.3 
      
5b t1 -116.5 (-4.02) 33.3 14.5 15.8 
 t2 -115.4 (-3.98) -10.1 0.0 0.0 
 t3 -115.9 (-4.00) 3.2 13.0 8.9 
      
5c t1 -114.3 (-3.94) 16.2 18.9 16.5 
 t2 -120.4 (-4.15) 43.3 6.5 1.3 
 t2 -114.6 (-3.95) -10.7 0.0 0.0 
 t3 -112.2 (-3.87) -0.5 13.8 13.1 
 t3 -110.5 (-3.81) -154.9 11.8 6.4 
a c.f. Table 2. b Normalized values as calculated using Eq. (1). c Numbering scheme for 
dihedral angle ω as shown in Table 2. 
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For the GPb-5a complex (Figure 3), as well as forming the standard hydrogen bonding 
interactions from the β-D-glucopyranosyl hydroxyl groups and a hydrogen bond from the 
carboxamide carbonyl O with the Leu136 backbone NH, through rotation around the dihedral 
angle ω the 1,2,4-triazole in its favored solution phase t2 tautomeric form has the potential to 
hydrogen bond with the Asp339 carboxylate on one side of the β-cavity (water-bridged), and 
on the other side directly with the Asp283 backbone O (ω ~ 50◦). If ω ~ 0◦  or ω ~ +/-180◦, 
although the 1,2,4-triazole NH forms no direct hydrogen bonds with GPb, there are favorable 
intra-molecular interactions from the carboxamide NH with the lone pair of electrons on a 
triazole N atom for both conformations, as mentioned earlier for the free state ligand (Figure 
2). The smaller Ar group (phenyl) of 5a also permits a flipped 1,2,4-triazole conformation (ω 
= -176.7◦) shown in Figure 4, where the triazole NH is a little longer than hydrogen bonding 
distance from the Glu88 sidechain carboxylate (distance ~ 3.3 Å).  Hence, 5a in its t2 
tautomeric state exhibits considerable conformational flexibility while bound at GPb 
(favorable in terms of entropy). The 1,2,4-triazole has either intra- and intermolecular 
hydrogen bonding potential in these different conformations; while CH-π interactions from 
the Asp283 CH to the ligand Ar (phenyl) group can further stabilize the GPb-5a complex 
(Figure 3). For the binding of ligand 5b (Figure 5), interactions are similar to that as described 
for 5a in Figure 3, except the 2-napthalene group extends deeper into the β-cavity. However, 
the larger size of this Ar group limits somewhat the conformational versatility (ω dihedral 
angle) of the ligand, and it has much fewer poses compared to either 5a and 5c (Table 3). For 
5c, the orientation of the 1-napthalene allows for greater conformational flexibility in the GPb 
binding site compared to its 2-napthalene equivalent, and indeed the t3 tautomer is able to 
adopt a pose (ω = -154.9◦; Table 3) similar to that shown for 5a in Figure 3, with a flip in the 
1,2,4-triazole.   
13 
 
 
 
                             
       
 
Figure 3. The lowest solution phase energy pose of ligand 5a (tautomer t2) bound at GPb 
with a dihedral angle (ω = 19.7◦; Table 3), as calculated using QM/MM and described in the 
text. 
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Figure 4. The flipped 1,2,4-triazole binding conformation of tautomer t2 of 5a at GPb 
(dihedral angle ω = -176.7◦; Table 3), as calculated using QM/MM and described in the text. 
The tautomeric t2 state allows for favorable intra-molecular hydrogen bond contacts between 
the carboxamide NH and a 1,2,4-triazole N when ω is close to 0◦ (Figure 2) or flipped 
(above). In the flipped conformation, the 1,2,4-triazole NH is close to hydrogen bonding 
distance with the Glu88 carboxylate.   
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Figure 5. The lowest solution phase energy pose of ligand 5b (tautomer t2) bound at GPb 
(dihedral angle ω = -10.1◦; Table 3), calculated using QM/MM as described in the text.  
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Synthesis 
Based on the computational results, synthesis of the ligands was considered worthwhile. 
Several methods have been published for the preparation of 3,5-disubstituted 1,2,4-triazoles.37 
While acyl-amidrazones (prepared from amides, thioamides, nitriles, or amidines) could be 
transformed into the desired triazoles under thermal conditions, 37-39 the cycloaddition of 
nitriles with nitrile-imines or nitrile-iminium ions gave 2,3,5-trisubstituted 1,2,4-triazoles in 
moderate to good yields.40-43 The reaction of 5-substituted tetrazoles with imidoyl chlorides 
(easily obtained from the corresponding amides by SOCl2) gave 3,4,5-trisubstituted 1,2,4-
triazoles in good yields. 44, 45 
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Scheme 1: Synthesis of the predicted molecules 5a,b 
This latter method was extensively applied for the preparation of 3-(C-glycosyl)-5-
substituted-1,2,4-triazoles in our group.13 The predicted target compounds of this study (5a,b) 
have been prepared using this methodology starting from tetrazole 616  as shown in Scheme 1. 
The imidoyl chlorides 10a,b and prepared from N-benzyl-amides 9a,b as described earlier,13 
were reacted with tetrazole 6 without any purification to give the corresponding 4-benzyl-N-
(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)-5-aryl-1,2,4-triazole-3-carboxamides 11a,b in 
moderate yields. In the case of the 1-naphthyl derivative 5c, the formation of 11c from 10c 
was unsuccessful, no transformation was detected and the desired compound has not been 
synthesized yet using any other synthetic methods. 
The protecting groups were cleaved in a two-steps procedure. The N-benzyl group of 11a,b 
was removed first by catalytic hydrogenation in excellent yields (94 and 85%). Subsequently, 
O-deacetylation was effected by the Zemplén method to give fully deprotected N-(β-D-
glucopyranosyl)-5-aryl-1,2,4-triazole-3-carboxamides 5a,b. 
 
Enzyme kinetics 
The inhibition constants (Ki) against rabbit muscle glycogen phosphorylase b (RMGPb) of  
compounds 5a,b were determined according to the protocol described earlier 46. The results 
are summarized in Table 1 together with the Ki’s of 1,2,4- and 1,3,4-oxadiazole-carboxamide 
type inhibitors. As the data shows, the 1,2,4-triazole analogues 5a (Ki = 1 µM) and 5b (Ki = 
9.2 µM) are more potent inhibitors than the oxadiazole analogues, consistent with our 
computational predictions for favorable binding at GPb.  
 
Pharmacokinetic Predictions 
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The early evaluation of the pharmacokinetic properties of lead compounds in drug design 
efforts is desirable due to the potential for failure in late stage clinical trials. Accordingly, the 
absorption, distribution, metabolism and excretion (ADME) properties of 5a-5c were 
predicted using the QikProp 3.5 program in normal mode.18 Toxicity is the leading cause of 
drug attrition in clinical trials, together with lack of efficacy.47 The FAF-Drugs2 server was 
used to extract any potential toxicity structural warnings.48 Results are shown in Table 4.  
 
An orally active drug should have no more than one violation of Lipinski’s ‘rule of five’,49 
while for Jorgensen’s ‘rule of three’ 50, 51 more drug-like molecules have fewer violations. The 
N-(β-D-glucopyranosyl)-1,2,4-triazolecarboxamides 5a-5c had only one violation of each. 
The Lipinski violation is due to too many hydrogen bond donors (HBDs), 6 instead of ≤ 5 in 
each case, but this is still within the range for 95% of known drugs and consistent with some 
recent ‘beyond rule of five’ studies.52, 53 In terms of Jorgensen’s rules, the Caco-2 cell 
permeability (> 22 nm s-1) is violated for the ligands (~ 19 nm s-1), where previously we noted 
that the sensitive balance between adequate lipophilicity and solubility may need attention in 
lead optimization of heterocyclic derivatives conjugated to glucose16. Meanwhile, the log 
Khsa’s (degree of human serum albumin affecting bioavailability) is ~ -0.9 – -0.7 and within 
the range for 95% of known drugs (-1.5 – 1.5), while the log BB (blood-brain barrier 
coefficients) values (-2.9 – -2.8) are also within the desirable range (-3.0 – 1.2). Importantly, 
there were no toxicity structural warnings for the ligands from FAF-Drugs2. Overall, the 
pharmacokinetic results are similar with the results for the N-(β-D-glucopyranosyl)-
oxadiazole-carboxamides previously reported.16 However, in terms of pharmacodynamics the 
5a,b ligands proved via kinetics experiments to be much more potent inhibitors of GP. 
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Table 4. Results of ADMET property predictions for the different tautomers of the N-(β-D-glucopyranosyl)-1,2,4-triazolecarboxamides inhibitors (5a-5c) studied in this work.[a]  
Inhibitor/       Lipinski’s Rule of Five and Violations (V)[b]     Jorgensen’s Rule of Three and Violations (V)[b]  PSA [Å2][c] log Khsa[d] log BB[e] TSW[f] 
  tautomer 
Mr [Da] 
(<500) 
HBD[g] 
(≤5) 
HBA[h] 
(≤10) 
log P(o/w) 
(<5) 
V Caco-2            
[nm s-1][i] 
(>22) 
log S 
(>-5.7) 
NMP[j] 
(<7) 
V  
(<140 Å2) 
   
          5a 
   
             
          t1 350.3 6 10 -1.6 1 19.2* -2.7 5 1 173.3 -1.02 -2.8 - 
          t2 350.3 6 10 -1.1 1 19.2* -2.8 5 1 173.3 -0.93 -2.8 - 
          t3 350.3 6 10 -1.4 1 18.9* -2.8 5 1 173.4 -0.97 -2.8 - 
              
          5b              
          t1 400.4 6 10 -0.8 1 19.2* -3.4 5 1 173.3 -0.85 -2.9 - 
          t2 400.4 6 10 -0.3 1 19.2* -3.6 5 1 173.2 -0.72 -2.9 - 
          t3 400.4 6 10 -0.6 1 19.0* -3.6 5 1 173.4 -0.80 -2.9 - 
              
          5c              
          t1 400.4 6 10 -0.8 1 18.2* -3.4 5 1 174.7 -0.85 -2.9 - 
          t2 400.4 6 10 -0.4 1 18.8* -3.6 5 1 174.2 -0.72 -2.9 - 
          t3 400.4 6 10 -0.7 1 18.3* -3.5 5 1 174.6 -0.80 -2.9 - 
Range[k] 130-725 0-6 2-20 -2.0-6.5 - <25 poor;              
> 500 great 
-6.5-0.5 1-8 - 7-200 -1.5-1.5 -3.0-1.2 - 
[a] ADMET data calculated using Qikprop 3.518; predicted properties outside the range for 95% of known drugs indicated with an asterisk (*). [b] Rules as listed in the columns, with 
any violations of the rules highlighted in italics. [c] PSA represents the van der Waals (polar) surface areas of N and O atoms; recommended PSA <140  Å2 according to Veber et al.54 [d] 
log Khsa: predicted binding to human serum albumin. [e] log BB: predicted blood-brain barrier coefficient. [f] Toxicity structural warnings from FAF-Drugs2.48 [g] Number of hydrogen 
bond donors. [h] Number of hydrogen bond acceptors. [i] Caco-2 cell permeability. [j] Number of primary metabolites. [k] Range for 95% of known drugs.18 
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Experimental 
Computational details (additional) 
Free ligand calculations: To determine the important (low energy) tautomeric 
forms/conformations of the model ligands 5 (Table 2), 1000 steps of  the Monte Carlo 
Multiple Minima (MCMM) method were performed using MacroModel 9.9,18 the OPLS-
AA(2005) forcefield33 and GB/SA continuum model for H2O solvation effects.55 The 
conformations were then optimized using DFT (M06-2X/6-31+G*) with Jaguar 8.018 and 
frequency calculations used to characterize the stationary points as true minima, as well as for 
calculation of the gas-phase Gibbs free energies at 298.15 K. For the solution phase QM 
calculations (M06-2X/cc-pVTZ++) 22 at these geometries, a SCRF continuum treatment of 
solvation with the PBF equation was used.24, 25   
Protein Preparation: The initial setup of the GPb receptor for calculations was performed 
using Schrodinger’s “Protein Preparation Wizard”18 starting from the GPb–1b co-crystallised 
complex. Water molecules were deleted, bond orders assigned, and hydrogen atoms added, 
with protonation states for basic and acidic residues based on residue pKa values at normal pH 
(7.0). Subsequent optimization of hydroxyl groups, histidine protonation states and C/N atom 
“flips”, and side-chain O/N atom flips of Asn and Gln was based on optimizing hydrogen 
bonding patterns. The phosphate in pyridoxal-phosphate (PLP) was assigned in monoanionic 
form. Finally, an “Impref” minimization of the GPb complex was performed using the OPLS-
AA(2005) force field33 to remove steric clashes and bad contacts but with heavy atoms 
constrained to within 0.3 Å (RMSD) of their crystallographic positions. 
Docking Details: For the Glide 5.8 docking calculations in extra-precision (XP) mode, the 
shape and properties of the GPb catalytic binding site were first mapped onto grids with 
dimensions of ~26.7 × 26.7 × 26.7 Å centred on the native co-crystallized ligand (1b). Core 
constraints (1 Å) on the six glucose ring atoms + the ligands’ amide moieties to retain them 
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close to the native ligand crystallographic positions were applied. Post-docking minimization 
of the ligand poses was performed (with strain correction) with a maximum of 5 poses per 
ligand saved. Poses were considered conformationally distinct for RMSDs (heavy atoms) > 
0.5 Å. 
 
Synthesis 
The general procedures employed for the synthesis are described in the ESI, together with the 
NMR data. 
 
GP Inhibition Assay 
Glycogen phosphorylase b was prepared from rabbit skeletal muscle according to the method 
of Fischer and Krebs56 using 2-mercaptoethanol instead of L-cysteine, and recrystallized at 
least three times before use. The kinetic studies with glycogen phosphorylase were performed 
as described previously.46  Kinetic data for the inhibition of rabbit skeletal muscle glycogen 
phosphorylase by monosaccharide compounds were collected using different concentrations 
of α-D-glucose-1-phosphate (4, 6, 8, 10, 12 and 14 mM) and constant concentrations of 
glycogen (1% w/v) and AMP (1 mM). The enzymatic activities were presented in the form of 
double-reciprocal plots (Lineweaver–Burk) applying a nonlinear data-analysis programme. 
The inhibitor constants (Ki) were determined by Dixon plots, by replotting the slopes from the 
Lineweaver–Burk plots against the inhibitor concentrations. The means of standard errors for 
all calculated kinetic parameters averaged to less than 10%. 3, 57 IC50 values were determined 
in the presence of 4 mM glucose 1-phosphate, 1 mM AMP, 1% glycogen, and varying 
concentrations of an inhibitor. 
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Conclusions 
Molecular modeling investigations in the form of docking, QM and QM/MM studies has 
motivated the experimental evaluation of N-(β-D-glucopyranosyl)-1,2,4-triazolecarboxamides 
as GP inhibitors. The value of QM calculations to determine favorable tautomeric states is 
highlighted, while QM/MM optimizations were used to decipher the more likely binding 
interactions in the absence of time consuming X-ray crystallographic evidence. While there is 
often uncertainty in assigning hydrogen positions using crystallography,58 QM/MM 
calculations allowed us to accurately consider the binding potential of the different 5a-5c 
1,2,4-triazole tautomers, with the GPb interactions formed by the most stable t2 tautomer and 
its conformational flexibility deemed  significant. Synthesis, followed by kinetics experiments 
revealed 5a,b as low µM inhibitors of GP, with 5a the in the top 10 most potent catalytic site 
inhibitor discovered to date.4 The N-(β-D-glucopyranosyl)-1,2,4-triazolecarboxamides are 
predicted to have drug-like potential, but with permeability a potential issue to efficacy. While 
intra-molecular bonding has the potential to improve membrane permeability by reducing the 
polar surface areas,52 this effect is likely to be minimal in our case. However, glucose 
analogues have already demonstrated blood glucose lowering effects in vivo, 10, 11 a large 
number of triazole compounds are found as clinical drugs or candidates for treatment of a 
range of diseases59, so that we consider the ligands studied worthy candidates for further 
optimization studies. Finally, the value of a computationally lead approach to GP inhibitor 
design has been highlighted in this work.27 
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